help button home button Am J Pathol Epitomics Buy 2 Antibodies Get 1 Free Special Offer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Favier, J.
Right arrow Articles by Gasc, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Favier, J.
Right arrow Articles by Gasc, J.-M.
(American Journal of Pathology. 2002;161:1235-1246.)
© 2002 American Society for Investigative Pathology

Regular Articles

Angiogenesis and Vascular Architecture in Pheochromocytomas

Distinctive Traits in Malignant Tumors

Judith Favier*, Pierre-François Plouin{dagger}, Pierre Corvol*{dagger} and Jean-Marie Gasc*

From the Collège de France and Institut National de la Santé et de la Recherche Médicale U36,* Paris; and the Département d’Hypertension Artérielle,{dagger} Hôpital Européen Georges Pompidou, Paris, France

Angiogenesis is a critical step in tumor growth and metastatic invasion. We here report the study of the vascular status of 10 benign and 9 malignant pheochromocytomas. We examined the vascular architecture after immunostaining endothelial cells (CD34) and vascular smooth muscle cells ({alpha}-actin) and identified a vascular pattern characteristic of malignant lesions. To define a gene expression profile indicative of the invasive phenotype, we studied by in situ hybridization the expression of genes encoding several pro- and anti-angiogenic factors [hypoxia-inducible factor (HIF-1{alpha}), EPAS1, vascular endothelial growth factor (VEGF), VEGF receptors, angiopoietins and their receptor Tie2, five genes of the endothelin system, and thrombospondin 1]. A semiquantitative evaluation of the labeling revealed an induction of genes encoding EPAS1, VEGF, VEGFR-1, VEGFR-2, endothelin receptor, type B (ETB) and endothelin receptor, type A (ETA) in malignant pheochromocytomas as compared to benign tumors. These differences were observed in tumor cells, in endothelial cells, or in both. Quantification by real-time reverse-transcriptase polymerase chain reaction showed an increase of EPAS1, VEGF, and ETB transcripts of 4.5-, 3.5-, and 10-fold, respectively, in malignant versus benign tumors. Furthermore, we observed a strong correlation between the expression of EPAS1 and VEGF in tumoral tissue and between EPAS1 and ETB in endothelial cells. Altogether, our observations show that analysis of angiogenesis provides promising new criteria for the diagnosis of malignant pheochromocytomas.




This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B Grossman
The diagnosis and management of malignant phaeochromocytoma and paraganglioma
Endocr. Relat. Cancer, September 1, 2007; 14(3): 569 - 585.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
J. C. Sluimer, N. Kisters, K. B. Cleutjens, O. L. Volger, A. J. Horrevoets, L. H. van den Akker, A.-P. J. Bijnens, and M. J. Daemen
Dead or alive: gene expression profiles of advanced atherosclerotic plaques from autopsy and surgery
Physiol Genomics, August 20, 2007; 30(3): 335 - 341.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Scholz, G. Eisenhofer, K. Pacak, H. Dralle, and H. Lehnert
Current Treatment of Malignant Pheochromocytoma
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1217 - 1225.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
H. AHLMAN
Malignant pheochromocytoma: state of the field with future projections.
Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 449 - 464.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Amar, A. Servais, A.-P. Gimenez-Roqueplo, F. Zinzindohoue, G. Chatellier, and P.-F. Plouin
Year of Diagnosis, Features at Presentation, and Risk of Recurrence in Patients with Pheochromocytoma or Secreting Paraganglioma
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2110 - 2116.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
G. Eisenhofer, S. R Bornstein, F. M Brouwers, N.-K. V Cheung, P. L Dahia, R. R de Krijger, T. J Giordano, L. A Greene, D. S Goldstein, H. Lehnert, et al.
Malignant pheochromocytoma: current status and initiatives for future progress
Endocr. Relat. Cancer, September 1, 2004; 11(3): 423 - 436.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. H. Kann, B. Wirkus, T. Behr, K.-J. Klose, and S. Meyer
Endosonographic Imaging of Benign and Malignant Pheochromocytomas
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1694 - 1697.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
G. Hopfl, O. Ogunshola, and M. Gassmann
HIFs and tumors--causes and consequences
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2004; 286(4): R608 - R623.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A.-P. Gimenez-Roqueplo, J. Favier, P. Rustin, C. Rieubland, M. Crespin, V. Nau, P. K. Van Kien, P. Corvol, P.-F. Plouin, and X. Jeunemaitre
Mutations in the SDHB Gene Are Associated with Extra-adrenal and/or Malignant Phaeochromocytomas
Cancer Res., September 1, 2003; 63(17): 5615 - 5621.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Society for Investigative Pathology.